



Supplemental Figure 2: Functional characterization and therapeutic testing of FR-Bh T cells: **A)** SKOV-6 Target cell number (left, n=2 wells/condition) and IFN- γ production (right, n=3/well) measured in a transwell assay. SKOV-6 target cells were plated in the lower chamber, with UTD or BiTE-producing T cells added to the upper/lower chambers as indicated. **B)** BiTE secretion by FR-Bh T cells at baseline and following acute or repeat antigen exposure (co-culture with SKOV-6 cells at a 4:1 E:T ratio). BiTE secretion by FR-Bh or UTD T cells (negative control) was measured over a 72hr period either at baseline or following co-culture (n=3 replicates/condition) **C)** SKOV-6 tumor growth following therapeutic delivery of 3×10^6 CONT-ENG or FR-Bh T cells, delivered by split dose injection (IV/Intratumoral delivery, n=3/group). Data presented as mean \pm SEM. Data in A) is from one representative experiment (two independent studies) and data in B & C) are from one experiment. A) One-way ANOVA, B) unpaired T test for each condition, C) Two-way ANOVA, ** p<0.01, *** p<0.001, **** p<0.0001